lung squamous cell carcinoma
Conditions
Interventions
Neoadjuvant therapy group:Research drug+chemotherapy neoadjuvant therapy
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18-75 years old; 2.ECOG behavior status score 0-1; 3.Diagnosed with squamous non-small cell lung cancer through cytology or histopathology; 4.All suspicious mediastinal lymph nodes, including those with pathological enlargement or increased FDG metabolism on PET/CT, require further sampling for pathological confirmation (if possible through EBUS or mediastinoscopy); 5.According to AJCC 9th edition, the clinical stage is II-IIIB, which has been evaluated as operable or potentially resectable; 6.According to RECIST 1.1 standard, it has measurable lesions; 7.The level of organ function must meet the following requirements: a. Bone marrow: absolute neutrophil count (ANC) >= 1.5 × 10^9/L, platelets >= 100 × 10^9/L, hemoglobin >= 9 g/dl; b. Good coagulation function: defined as International Normalized Ratio (INR) or Prothrombin Time (PT) = 60 ml/min; 8.According to the assessment of the surgeon, the patient's lung function can tolerate the planned lobectomy surgery; 9.Women of childbearing age must undergo a pregnancy test with a negative result within 7 days before starting treatment, and take contraceptive measures during and within 3 months after treatment; Male of childbearing age: Take contraceptive measures during and within 3 months after surgical sterilization or treatment; 10.Understand and voluntarily sign a written informed consent form;
Exclusion criteria
Exclusion criteria: 1.There are locally advanced, unresectable, or metastatic diseases present; 2.Previously received any systemic anti-tumor therapy, including chemotherapy, radiotherapy, immunotherapy, or targeted therapy; 3.Patients with active, known or suspected autoimmune diseases or immunodeficiency; 4.Previous interstitial lung disease, drug-induced interstitial pneumonia, or any clinically proven active pneumonia/interstitial lung disease; 5.History of active pulmonary tuberculosis; 6.According to the researchers' assessment, there are any unstable systemic diseases present; 7.Uncontrolled active hepatitis B infection; 8.The patient previously suffered from other malignant tumors (except for fully treated basal cell or squamous cell skin cancer and the following in situ cancers: bladder cancer, gastric cancer, intestinal cancer, endometrial cancer, cervical/dysplasia, melanoma or breast cancer); 9.Known to have human immunodeficiency virus (HIV) infection; 10.Known severe allergy to QL1706, investigational chemotherapy drugs, and/or any of their excipients;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathological remission;R0 resection rate;Event-free survival;Clinical response rat;Overall survival; | — |
Countries
China
Contacts
Public ContactJian Zeng
Zhejiang Cancer Hospital
Outcome results
None listed